<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Ampicillin - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Ampicillin</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Ampicillin</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Ampicillin 500mg Injection</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Respiratory tract infections (mild-moderate pneumonia)</strong>
            <ul>
              <li>250–500 mg IM/IV every 6 hours</li>
              <li>Severe infections: up to 1–2 g IV every 4–6 hours</li>
            </ul>
          </li>
          <li><strong>Sepsis / severe infections</strong>
            <ul>
              <li>1–2 g IV every 4–6 hours (in combination with other antibiotics as per clinical guidelines)</li>
            </ul>
          </li>
          <li><strong>Bacterial meningitis (suspected/confirmed)</strong>
            <ul>
              <li>2 g IV every 4 hours (urgent medical evacuation required; follow local protocols)</li>
            </ul>
          </li>
          <li><strong>Endocarditis (streptococcal)</strong>
            <ul>
              <li>Dosing varies; typically 2 g IV every 4–6 hours in combination therapy (follow infectious disease guidance)</li>
            </ul>
          </li>
          <li><strong>Urinary tract infections</strong>
            <ul>
              <li>250–500 mg IM/IV every 6 hours (if oral therapy not appropriate)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Susceptible bacterial infections including respiratory tract, urinary tract, GI, and soft tissue infections</li>
          <li>Listeria monocytogenes infections</li>
          <li>Enterococcal infections (often in combination therapy)</li>
          <li>Bacterial meningitis (in combination with other antibiotics)</li>
          <li>Sepsis when susceptible organisms suspected (empiric or directed therapy)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>History of immediate hypersensitivity to penicillins or beta-lactam antibiotics</li>
          <li>Cross-reactivity with cephalosporins possible (caution based on reaction severity)</li>
          <li>Infectious mononucleosis or other viral infections (high risk of rash with aminopenicillins)</li>
          <li>Dose adjustment required in significant renal impairment</li>
          <li>C. difficile-associated diarrhea risk: monitor for severe diarrhea during/after therapy</li>
          <li>Drug interactions: may increase methotrexate levels; may reduce effectiveness of oral contraceptives</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI upset (nausea, vomiting, diarrhea)</li>
          <li>Rash (particularly in infectious mononucleosis)</li>
          <li>Hypersensitivity reactions ranging from urticaria to anaphylaxis</li>
          <li>Pain at injection site (IM); thrombophlebitis (IV)</li>
          <li>C. difficile-associated diarrhea</li>
          <li>Rarely: seizures (with high doses, especially in renal impairment or meningitis)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>IM administration:</strong> Reconstitute 500 mg vial with 1.8 mL sterile water for injection to yield 250 mg/mL. Inject deep IM into large muscle mass</li>
          <li><strong>IV administration:</strong> Reconstitute and dilute as per product monograph. May give by slow IV push (over 3–5 minutes) or IV infusion (over 15–30 minutes)</li>
          <li>Use freshly prepared solutions; stability varies (check product monograph for reconstitution stability)</li>
          <li>Administer at evenly spaced intervals to maintain therapeutic levels</li>
          <li>Monitor injection sites for signs of local reactions or phlebitis</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response within 48–72 hours (fever curve, symptoms, vital signs)</li>
          <li>Allergic reactions: watch for rash, urticaria, bronchospasm, or signs of anaphylaxis</li>
          <li>Injection site reactions (pain, swelling, phlebitis)</li>
          <li>Diarrhea severity (consider C. difficile if severe or persistent)</li>
          <li>Renal function in prolonged therapy or high-risk patients when feasible</li>
          <li>CNS effects (confusion, seizures) especially in renal impairment or high-dose therapy</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Reserve for serious infections when parenteral therapy required and oral options inadequate</li>
          <li>Ensure proper storage and check expiry dates; reconstituted solutions have limited stability</li>
          <li>Document allergy history carefully before administration</li>
          <li>Have epinephrine and resuscitation equipment available due to anaphylaxis risk</li>
          <li>For severe infections requiring ampicillin, plan early for medical evacuation as appropriate</li>
          <li>If limited diagnostic capacity, reassess non-response early and escalate care</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (ampicillin for injection): <a href="https://pdf.hres.ca/dpd_pm/00046916.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00046916.PDF</a></li>
          <li>Medscape drug reference (ampicillin): <a href="https://reference.medscape.com/drug/principen-ampicillin-342476" target="_blank" rel="noopener">https://reference.medscape.com/drug/principen-ampicillin-342476</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
